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Abstract Purpose: Early lung
recruitment (ELR) during high-fre-
quency oscillatory ventilation
(HFOV) in combination with
prophylactic surfactant use has been
reported to reduce mortality, improve
respiratory outcomes, and reduce the
need for repeated surfactant dosing,
suggesting that surfactant might be
used more selectively in very low
birth weight (VLBW) infants on
HFOV than generally recommended.
We report our first experience from
such a selective early rescue use of
surfactant in VLBW infants on
HFOV. Methods: After a deliberate
ELR maneuver and ‘‘optimal’’
continuous distending pressure (CDP)
finding during HFOV, used as
primary ventilation mode for VLBW
infants with respiratory distress
syndrome (RDS), surfactant was only
given when an unsatisfactory oxy-
genation response to lung recruitment
(as defined by CDP 9 FiO2 [ 5) was
observed. Results: Out of 144
VLBW infants on HFOV, 84 (58.3%)
received surfactant and 60 (41.7%)
did not. Duration of required oxygen
supplementation (37.4 ± 44.9 vs.
46.2 ± 35.4 days; P = 0.031) and
respiratory support (i.e., n-CPAP
and/or mechanical ventilation;
22.3 ± 19.3 vs. 38.2 ± 24.3 days;
P = 0.001) was shorter for infants
who did not receive surfactant than
for those who did. The incidence and
severity of bronchopulmonary
dysplasia was similar in both groups,
and there was no difference in sur-
vival rates between groups. Subgroup
analysis for infants of less than
28 weeks of gestation revealed
similar results. Conclusions: First
intention HFOV combined with an
early attempt at lung volume optimi-
zation might allow surfactants to be
used more selectively (in relation to
disease severity) in VLBW infants
presenting with RDS at birth without
negatively influencing the outcome.
Keywords Respiratory failure 
High-frequency oscillatory
ventilation  Preterm newborn infant 
Surfactant  Patent ductus arteriosus 
Nasal continuous positive airway
pressure  Patient outcome assessment
Introduction
There is growing evidence that the ventilator strategy
used during mechanical ventilation may influence pul-
monary outcome in preterm infants with respiratory
distress syndrome (RDS). Several reports of early lung
recruitment (ELR) during high-frequency oscillatory
ventilation (HFOV) suggest a benefit of such a strategy in
terms of improving pulmonary outcome [i.e., occurrence
of bronchopulmonary dysplasia (BPD), oxygen depen-
dency, and duration of ventilation] in preterm infants with
RDS [1–3]. However, with the increasing use of lung-
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protective ventilator strategies during conventional
mechanical ventilation (CMV), the benefit of HFOV is
not as clear-cut [4, 5]. During the transition towards more
gentle (e.g., lung-protective) ventilation over the last
years, indications for surfactant that were established
almost 2 decades ago might need to be rethought based on
some clinical and experimental observations. Accord-
ingly, systematic prophylactic surfactant administration
has been challenged recently, considering that it exposes
to intubation and ventilation some premature infants who
might be managed perfectly on nasal continuous positive
airway pressure (n-CPAP) [6]. Furthermore, Moriette and
colleagues [7] have demonstrated a reduction in the need
for supplemental surfactant doses when HFOV combined
with an open-lung strategy was used. Similarly, Vento
et al., in a recent randomized trial, showed that early and
exclusive use of HFOV combined with optimum volume
strategy allowed for early and sustained improvement in
pulmonary mechanics and gas exchange with earlier
extubation as compared to neonates assigned to CMV
treatment and reduced the need in the HFOV group for a
second surfactant dose [8]. In experimental settings, lung-
protective ventilation strategies seem to preserve surfac-
tant activity better than injurious ventilation strategies
[9–11]. Based on these observations, it might be justified
to question the commonly accepted indications for sur-
factant treatment when HFOV combined with an ELR
approach is initiated immediately after intubation in pre-
term infants presenting with RDS at birth. We report our
experience and outcome data over a 9 year observation
period with a restricted selective use of surfactant in this
patient population.
Materials and methods
Patients
Over a 9-year observational period, all consecutively
admitted inborn neonates with a gestational age
\32 weeks and a birth weight \1,500 g who developed
early RDS (within the first 24 h of life) requiring
mechanical ventilation were identified from a prospec-
tively maintained database. Indication for tracheal
intubation was decided based on clinical criteria [i.e.,
persisting severe respiratory distress with CO2 retention
[8 kPa (60 mmHg) and/or oxygen requirement (FiO2)
[0.5 while on n-CPAP, irrespective of the timing of
intubation]. While on n-CPAP, positive pressure level
was set between 4 and 8 cm H2O according the attending
physician’s decision. Our target tSO2 for O2 supplemen-
tation was 88–92%, accepting a minimum of 85% over
short periods. Neonates with hydrops fetalis, congenital
lung and heart malformations, chromosomopathies, or
congenital diaphragmatic hernia were excluded from
analysis. For analysis, patients were subdivided into those
who received surfactant therapy and those who did not.
The HFOV-based ventilator strategy has been our
primary ventilatory mode for premature infants presenting
with RDS since 1997 and was established as such by a
consensus agreement among staff physicians [3]. Detailed
treatment strategies can be found in the Electronic Sup-
plementary Material.
Data collection
Demographic data, ventilator parameters, gas exchange,
and outcome variables were collected for each patient by
chart review. Uniformity between groups was evaluated
based on gestational age, birth weight, the use of antenatal
steroids, and Apgar scores at 1 and 5 min.
Endpoints
The following primary endpoints were evaluated for dif-
ferences in morbidity and outcome between the two
groups: (1) length of mechanical ventilation and total time
of respiratory support, including n-CPAP (days), (2)
length of supplemental oxygen requirements (days), (3)
occurrence of mild, moderate, and severe BPD [12], and
(4) survival. Survival was assessed at 30 days, 36 weeks
PMA, and at discharge. Combined mortality including
death and occurrence of severe BPD was also assessed.
Secondary endpoints for assessment of possible adverse
effects were (1) intraventricular hemorrhage, (2) air leak
syndrome (pneumothorax, pulmonary interstitial emphy-
sema), (3) sepsis and necrotizing enterocolitis, and (4)
occurrence of a hemodynamically significant patent
ductus arteriosus (hsPDAS, always confirmed by
echocardiography).
Statistical analysis
Continuous data were expressed as mean ± standard
deviation (SD). A two-tailed Fishers’ exact test was used
for categorial data. Nonparametric Mann-Whitney U test
was used for continuous data. For all testing, a P value
\0.05 was accepted as significant. Statistical analysis was
performed using a Systat 10.0, SPSS package.
Results
Between 1 January 1997 and 31 December 2005, 620
very low birth weight (VLBW) infants were delivered in
our institution (Fig. 1). Among those, 144 infants
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[including 96 (67%) with a gestational age of less than
28 weeks] presenting with early RDS as a primary diag-
nosis required invasive mechanical ventilation: 93
(64.7%) were intubated in the delivery room after failing
an initial n-CPAP trial (delay to intubation:
0.99 ± 2.7 h), and 51 infants (35.3%) were intubated
later on while failing n-CPAP (delay to intubation:
18.8 ± 14.9 h) (P \ 0.001). After intubation, all infants
were put in a first intention on HFOV [1–3]. After an
initial lung recruitment procedure on HFOV, 84 infants
(58.3%) received selective early rescue surfactant therapy
according to our criteria (i.e., CDP 9 FiO2 [ 5) and the
other 60 infants (41.7%) with a CDP 9 FiO2 B 5 did not
receive surfactant. Fifty-seven (67.8%) of these 84 infants
treated with surfactant received Curosurf, while the
remaining had Exosurf (n = 27, 31.4%). Whereas no
statistical differences in most respiratory outcomes were
found between the two surfactant types in treated infants,
oxygen dependency was shorter in infants who received
Exosurf than Curosurf (21.4 ± 23 vs. 39.5 ± 37 days;
P = 0.024). Between the two groups (surfactant vs. no
surfactant), no differences were noted in demographic
data (gestational age, birth weight, and gender), incidence
of prenatal steroid treatment, or low Apgar score at 1 and
5 min (Table 1). n-CPAP as a first respiratory support
option (i.e., no intubation in the labor room) was more
often used in the group of patients who, according to our
criteria, would later require early rescue surfactant (36/84
vs. 15/60; P = 0.034). Overall mean time delay of intu-
bation after delivery between the surfactant and the no-
surfactant group was longer in patients who did receive
surfactant than in those who did not (9.8 ± 13.4 vs.
6.4 ± 12.5 h; P = 0.01). Both observations suggest a
higher need for early rescue surfactant when n-CPAP was
used in a first intention in order to avoid intubation (OR
2.25, 95% CI 1.09–4.65; P = 0.042).
Outcome
Detailed pulmonary outcome data in survivors are given
in Table 2. Both overall respiratory support and oxygen
dependency were shorter in patients who did not receive
surfactant, whereas overall duration on mechanical ven-
tilation was not different between groups. No statistically
significant difference was found between groups for the
incidence of mild, moderate, and severe BPD, although a
trend could be observed in favor of the no-surfactant
group. There were no differences between the groups
in the incidence of mild or severe intraventricular
hemorrhage (IVH), pulmonary air leaks, necrotizing
enterocolitis, or sepsis (Table 3). However, hsPDA was
observed less often in patients who received no surfactant
than in those who received surfactant (58.3 vs. 78.6%;
P = 0.01). Survival was similar in both groups as well as
in the combined outcome (Table 4). The cause of death in
the four patients who died between 30 days and discharge
was multiorgan failure related to septic shock in three
cases and Intraventricular hemorrhage (IVH) grade 4 in
one. All four patients had been weaned from HFOV and
were on n-CPAP before the acute event that led them to
the dismal outcome occurred.
In infants of \28 weeks of gestational age, 57 (59%)
received surfactant. Patient’s characteristics were similar
between both groups. Delay of intubation was shorter in
patients without surfactant (5.8 ± 12.1 vs. 9.3 ± 13.9 h;
P = 0.048). More hsPDA occurred in patients who
received surfactant than in others. No other outcome
criterion was found to be significantly different between
the two groups (Table 5).
Discussion
Our results suggest that when an ELR strategy is used
successfully in conjunction with HFOV, prophylactic
surfactant treatment might not be systematically required
in VLBW infants presenting with RDS at birth. Indeed,
not using surfactant in every VLBW case—even for
infants of less than 28 weeks of gestational age presenting
with RDS at birth who needed mechanical ventilation and
were ventilated with HFOV—did not negatively affect
respiratory outcome or mortality in our patient collective.
The decision to administer surfactant was based on
disease severity as assessed by the continuous distending
pressure (CDP) required after a formal RM attempt to
achieve a specific oxygenation goal at a relatively low
Fig. 1 Studied population. VLBW Very low birth weight, RDS
respiratory distress syndrome, nCPAP nasal continuous positive
airwaypressure, HFOV high-frequency oscillatory ventilation
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Table 1 Patient characteristics
No surfactant
(n = 60)
Surfactant
(n = 84)
P value
Birth weight (g) 960.7 ± 264.5 946.3 ± 274.6 0.788
Gestational age (weeks) 27.4 ± 1.9 27.4 ± 1.8 0.976
Antenatal steroid treatment, n (%) 29 (48.3) 40 (47.6) 0.610
Apgar score \4 at 1 min, n (%) 25 (41.7) 34 (40.5) 1.000
Apgar score \6 at 5 min, n (%) 18 (30) 17 (20.2) 0.237
Initial n-CPAP, n (%)a 15 (25) 36 (42.8) 0.034
Overall delay to intubation (h) 6.4 ± 12.5 9.8 ± 13.4 0.01
n-CPAP Nasal continuous positive airway pressure
a Intubation delay in patients with initial n-CPAP: no surfactant 19.8 ± 15.7 h versus surfactant 18.1 ± 14.6 h; P = NS
Table 2 Primary outcome in survivors
No surfactant
(n = 43)
Surfactant
(n = 61)
P value
Duration on HFOV (days) 5.1 ± 7.3 7.7 ± 9.6 0.088
Total respiratory support (days)a 22.3 ± 19.3 38.2 ± 24.3 0.001
Duration of oxygen dependency (days) 37.4 ± 44.9 46.2 ± 35.4 0.031
Mild BPD (oxygen dependency at 28 days), n (%) 12 (27.9) 22 (36) 0.382
Moderate BPD (oxygen dependency
at 36 weeks PMA), n (%)
1 (2.3) 7 (11.4) 0.081
Severe BPD (oxygen dependency and use
of ventilatory support at 36 weeks PMA), n (%)
2 (4.6) 5 (14.7) 0.477
HFOV High-frequency oscillatory ventilation, BPD bronchopulmonary dysplasia, PMA post-menstrual age
a Respiratory support: nCPAP and mechanical ventilation
Table 3 Secondary outcome
Survivors All patients
No surfactant
(n = 43)
Surfactant
(n = 61)
P value No surfactant
(n = 60)
Surfactant
(n = 84)
P value
IVH grade 1 or 2, n (%) 11 (25.6) 18 (29.5) 0.660 15 (25) 20 (23.7) 0.870
IVH grade 3, n (%) 3 (6.9) 6 (9.8) 0.328 3 (5) 6 (7.1) 0.600
IVH grade 4, n (%) 4 (9.3) 1 (1.6) 0.157 12 (20) 8 (9.5) 0.089
Air leak syndrome, n (%)a 8 (18.6) 15 (24.6) 0.623 10 (16.7) 18 (21.4) 0.528
Sepsis, n (%) 16 (37.2) 34 (55.7) 0.075 24 (40) 42 (50) 0.309
Necrotizing enterocolitis, n (%) 3 (7) 5 (8.1) 1.000 4 (6.7) 7 (8.3) 0.763
hsPDA, n (%) 27 (62.8) 50 (82) 0.04 35 (58.3) 66 (78.6) 0.01
IVH Intraventricular hemorrhage, hsPDA hemodynamically significant patent ductus arteriosus
a Air leak syndrome: pneumothorax or interstitial emphysema
Table 4 Overall survival
No surfactant
(n = 60)
Surfactant
(n = 84)
P value
Survival to 30 days, n (%) 46 (76.7)a 62 (73.8) 0.845
Survival to 36 weeks PMA, n (%) 43 (71.7)a 61 (72.6) 1.000
Survival to discharge, n (%) 43 (71.7)a 61 (72.6) 1.000
Combined mortality, n (%)b 19 (31.6) 33 (39.3) 0.383
PMA Post-menstrual age
a Additional death secondary to septic shock and multiorgan failure (n = 3) and bilateral IVH grade 4 (n = 1)
b Combined mortality: death or severe BPD
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CDP while on low oxygen concentration (i.e.,
CDP 9 FiO2 B 5) [13]. The rationale behind this
approach is that (1) an easily recruitable lung in the early
stage of RDS may not need exogenous surfactant treat-
ment for sufficient lung opening, and (2) gentle
ventilation in an ‘‘open lung’’ may preserve surfactant
function by avoiding a major inflammatory stimulus
within the lungs, as suggested by experimental data [14–
19]. Van Kaam and co-workers [20] have shown in an
animal model of neonatal lung injury that using an open-
lung strategy during both HFOV or CMV performed
better in regards to dose-dependent efficacy of surfactant
with less surfactant inactivation than CMV without
applying an open-lung strategy. Similarly, Hilgendorff
et al. [21] in an animal model showed that open-lung
ventilation alone did better than surfactant and conven-
tional ventilation. Human data confirmed the efficacy of
HFOV recruitment maneuver in improving both func-
tional lung capacity [22, 23] and inflammatory lung
profiles [24, 25]. Furthermore, in two recent randomized
controlled trials comparing HFO with CMV [7, 8], ELR
during HFOV allowed the number of repeated surfactant
doses in VLBW infants with RDS to be reduced com-
pared to infants assigned to conventional ventilation who
were not submitted to a lung recruitment attempt.
Besides appropriate lung recruitment, the timing of
HFOV initiation seems to influence outcome too. Using
ELR with HFOV compared to CMV in a recent ran-
domized trial in VLBW infants with RDS demonstrated
an early and sustained improvement in pulmonary
mechanics and gas exchange, as well as a significant trend
towards a reduced oxygen dependency at 36 weeks PMA
[8]. Similarly, Mehta et al. [26] and Derdak et al. [27] in
adult patients and Fedora et al. [28] in children with acute
RDS showed better survival in patients who were swit-
ched from CMV to HFOV early in the course of disease
when compared to those that were switched to HFOV
after several days of CMV. These observations suggest
that prolonged ventilation with a potentially injurious
ventilatory strategy may aggravate lung injury and alter
efficiency of subsequent therapy. Similarly, in our series,
lung recruitment became more difficult in infants who
were initially put on n-CPAP for a prolonged time before
intubating and initiating HFOV, as illustrated by the
increased use of surfactant, indicating that lung injury
might worsen during prolonged n-CPAP application in
babies presenting with an important RDS. Accordingly,
some recent papers strongly suggest that lung injury can
be initiated or worsened not only by positive pressure
ventilation but also during spontaneous breathing
[29, 30].
In our patient series, a more restrictive use of surfac-
tant after ELR was significantly associated with a lower
incidence of hsPDA (OR 5.91, 95% CI 1.26–5.44;
P = 0.015). Several authors identified hsPDA as a major
risk factor for the development of chronic lung disease
[31–34]. Recently, Noori et al. showed that hsPDA
(hazard ratio 8.34; 95% CI 4.30–16.06) is associated with
increased mortality in VLBW infants of \28 weeks of
gestational age [35]. However, it is not clear whether
surfactant therapy has an impact on the development of
hsPDA [36, 37].
Some limitations of our study should be mentioned.
First, interpretation of our results is limited by the cohort
study design and a selection bias: only VLBW infants
with early RDS (\24 h) were included, representing 23%
of the 620 VLBW infants delivered in our institution
over the same time period. Furthermore, surfactant was
Table 5 Outcomes analysis of infants of \28 weeks gestational age
No surfactant
(n = 39)
Surfactant
(n = 57)
P value
IVH grade 4, n (%) 9 (23) 5 (8.8) 0.051
Air leak syndrome, n (%)a 5 (12.8) 9 (15.7) 0.686
Sepsis, n (%) 22 (56) 34 (59.4) 0.752
Necrotizing enterocolitis, n (%) 4 (10.2) 6 (10.5) 0.966
hsPDA, n (%) 24 (61.5) 46 (80.7) 0.038
Duration on HFOV (days)b 7 ± 10 8.9 ± 11.4 0.565
Total respiratory support (days)b 34.3 ± 18.9 48.5 ± 23.6 0.175
Duration of oxygen dependency (days)b 52.1 ± 51.2 61.1 ± 35.7 0.347
Mild BPD, n (%)b 8 (36.4) 19 (51.3) 0.264
Moderate BPD, n (%)b 1 (4.5) 3 (8.1) 0.599
Severe BPD, n (%)b 2 (9.1) 5 (13.5) 0.944
Survival to 30 days, n (%) 25 (64.1) 38 (66.7) 0.795
Survival to 36 weeks PMA, n (%) 22 (56) 37 (64.9) 0.401
Survival to discharge, n (%) 22 (56) 37 (64.9) 0.401
Combined mortality, n (%)c 19 (48.7) 30 (52.6) 0.706
IVH Intraventricular hemorrhage, hsPDA hemodynamically sig-
nificant patent ductus arteriosus, HFOV high-frequency oscillatory
ventilation, BPD bronchopulmonary dysplasia, PMA post-men-
strual age
a Air leak syndrome: pneumothorax or interstitial emphysema
b In survivors (no surfactant n = 22, surfactant n = 37)
c Combined mortality: death or severe BPD
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administered only on a selective basis as an ‘‘early rescue
therapy’’ in patients who failed to be efficiently recruited
according to our criteria (CDP 9 FiO2 B 5 after RM). As
a result, surfactant was used in the most severe cases (i.e.,
in those who were not recruitable according our criteria)
with an early rescue approach. It could be argued that
administering surfactant to all patients independent of
their response to recruitment—which would correspond
to a much more prophylactic approach—might have
improved our good outcome results still further. On the
other hand, the more restrictive use of surfactant we
describe may have a substantial economic impact due to
the reduction of direct cost for surfactant preparation and
potential indirect cost for medical and surgical PDA
closure procedures.
In summary, our outcome data show that implemen-
tation of an ELR strategy with HFOV allows for a
selective use of surfactant based on the oxygenation
response after lung recruitment during HFOV, with no
detrimental effect on respiratory outcomes and mortality
in VLBW infants presenting with RDS. Although one
should consider that our patients can be divided into two
groups by disease severity with the less sick patients
showing better outcome independent of surfactant treat-
ment, three important issues will need further assessment
in well designed controlled clinical trials: (1) Does the use
of an ELR during HFOV, as a lung-protective strategy,
really allow exogenous surfactants to be used more
selectively in VLBW infants with RDS without nega-
tively affecting respiratory outcome or survival? (2) Does
delaying intubation in a subgroup of infants who require
intubation eventually negatively affect outcome? (3) Does
initial n-CPAP in VLBW infants with RDS hamper sec-
ondary lung recruitment with HFOV?
The commonly accepted surfactant indications that
were established years ago might need to be reviewed
within the context of recently established lung-protective
ventilation strategies, thereby providing the rationale for a
well-designed randomized trial.
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